Orgenesis Stock Performance

ORGS -  USA Stock  

USD 4.78  0.13  2.65%

Orgenesis has performance score of 2 on a scale of 0 to 100. The company holds a Beta of 2.8656, which implies a somewhat significant risk relative to the market. Let's try to break down what Orgenesis's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Orgenesis will likely underperform. Although it is extremely important to respect Orgenesis current trending patterns, it is better to be realistic regarding the information on equity existing price patterns. The philosophy towards forecasting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Orgenesis technical indicators, you can presently evaluate if the expected return of 0.17% will be sustainable into the future. Orgenesis right now holds a risk of 5.56%. Please check Orgenesis downside variance, and the relationship between the sortino ratio and accumulation distribution to decide if Orgenesis will be following its historical price patterns.

Search Stock Performance 

 
Refresh
 Orgenesis Performance
2 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Orgenesis are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady technical and fundamental indicators, Orgenesis may actually be approaching a critical reversion point that can send shares even higher in August 2021. ...more

Orgenesis Price Channel

Quick Ratio2.82
Fifty Two Week Low4.1400
Target High Price9.00
Fifty Two Week High8.3000
Target Low Price9.00

Orgenesis Relative Risk vs. Return Landscape

If you would invest  471.00  in Orgenesis on April 29, 2021 and sell it today you would earn a total of  7.00  from holding Orgenesis or generate 1.49% return on investment over 90 days. Orgenesis is currently generating 0.1689% in daily expected returns and assumes 5.559% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Orgenesis, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Orgenesis is expected to generate 7.42 times more return on investment than the market. However, the company is 7.42 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The DOW is currently generating roughly 0.07 per unit of risk.

Orgenesis Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Orgenesis' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Orgenesis, and traders can use it to determine the average amount a Orgenesis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0304

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsORGS
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns
Estimated Market Risk
 5.56
  actual daily
 
 47 %
of total potential
 
4747
Expected Return
 0.17
  actual daily
 
 3 %
of total potential
 
33
Risk-Adjusted Return
 0.03
  actual daily
 
 2 %
of total potential
 
22
Based on monthly moving average Orgenesis is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orgenesis by adding it to a well-diversified portfolio.

About Orgenesis Performance

To evaluate Orgenesis Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Orgenesis generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Orgenesis Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Orgenesis stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Orgenesis's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies . The company was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people.

Things to note about Orgenesis

Checking the ongoing alerts about Orgenesis for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Orgenesis help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Orgenesis Alerts

Equity Alerts and Improvement Suggestions

Orgenesis has very high historical volatility over the last 90 days
Orgenesis has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 15.16 M. Net Loss for the year was (83.17 M) with profit before overhead, payroll, taxes, and interest of 7.65 M.
Orgenesis currently holds about 41.84 M in cash with (68.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71.
Latest headline from finance.yahoo.com: Would Shareholders Who Purchased Orgenesis Stock Three Years Be Happy With The Share price Today - Yahoo Finance
Please check Your Equity Center. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Orgenesis Stock analysis

When running Orgenesis price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine Orgenesis value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.